Skip to Content

Myelin-specific T-cells as biomarker in multiple sclerosis patients treated with natalizumab

Barbara Willekens, Neurologist, and postdoc researcher, presents a prospective longitudinal cohort study in patients with RRMS treated with natalizumab. The study analyzes if myelin-specific T-cells in blood can be used as biomarker to assess and predict immunomodulatory effect of antigen specific treatment in patients. In conclusion, measured T-cell reactivity was not stable over time, hence future studies measuring other cytokine signatures may be next step. Read more: P609 Longitudinal analysis of autoreactive T cells in a cohort of multiple sclerosis patients treated with natalizumab

Barbara Willekens

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top